Can dacomitinib be considered after erlotinib resistance?

After resistance to erlotinib, dacomitinib can be considered, but whether it is appropriate depends on the patient's specific situation and the doctor's advice.

Erlotinib and dacomitinib are both epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and are mainly used to treat non-small cell lung cancer with EGFR gene mutations. Their mechanism of action is to prevent the growth and proliferation of tumor cells by inhibiting the activity of EGFR.

However, due to the heterogeneity of tumor cells and differences in drug action mechanisms, patients may develop drug resistance after taking erlotinib for a period of time. When resistance to erlotinib occurs, doctors may consider switching to other EGFR tyrosine kinase inhibitors, such as dacomitinib, to continue to inhibit the EGFR signaling pathway.

Dacomitinib, as a second-generation, irreversible EGFR tyrosine kinase inhibitor, has stronger inhibitory effects and longer duration than first-generation drugs such as erlotinib. In some cases, dacomitinib may still be effective in patients who are resistant to erlotinib.

However, it should be noted that dacomitinib is not effective in all patients who are resistant to erlotinib. The resistance mechanism may vary depending on individual differences, including EGFR T790M mutation, activation of alternative signaling pathways and other reasons. Therefore, before deciding to use dacomitinib, patients need to undergo further genetic testing and other related examinations to clarify the resistance mechanism and the suitability of dacomitinib.

In addition, the use of dacomitinib may also be associated with certain side effects, such as rash, diarrhea, liver function damage, etc. Patients need to pay close attention to body reactions during use and make reasonable dosage adjustments and side effects management under the guidance of a doctor.